VIR Q3 2021 Earnings — Vir Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

VIRVir Biotechnology, Inc.

$1B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$104M+55014.9% YoY

Gross Profit

-$3M-2.8% margin

Operating Income

-$53M-51.5% margin

Net Income

$110M106.6% margin

EPS (Diluted)

$0.82

QoQ Revenue Growth

-41.5%

Cash Flow

Operating Cash Flow

-$106M

Free Cash Flow

-$112M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$334M

Stockholders' Equity

$876M

Cash & Equivalents

$715M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$104M	$188,000	+55014.9%
Gross Profit	-$3M	$188,000	-1636.7%
Operating Income	-$53M	-$88M	+39.1%
Net Income	$110M	-$85M	+230.5%

Revenue Segments

Collaboration Revenue

$102M100%

Contract Revenue

$315,0000%